Cargando…

Updates on the Diagnosis and Management of Glaucoma

Glaucoma is the leading cause of blindness throughout the world (after cataracts); therefore, general physicians should be familiar with the diagnosis and management of affected patients. Glaucomas are usually categorized by the anatomy of the anterior chamber angle (open vs narrow/closed), rapidity...

Descripción completa

Detalles Bibliográficos
Autores principales: Wagner, Isabella V., Stewart, Michael W., Dorairaj, Syril K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673042/
https://www.ncbi.nlm.nih.gov/pubmed/36405987
http://dx.doi.org/10.1016/j.mayocpiqo.2022.09.007
_version_ 1784832865843806208
author Wagner, Isabella V.
Stewart, Michael W.
Dorairaj, Syril K.
author_facet Wagner, Isabella V.
Stewart, Michael W.
Dorairaj, Syril K.
author_sort Wagner, Isabella V.
collection PubMed
description Glaucoma is the leading cause of blindness throughout the world (after cataracts); therefore, general physicians should be familiar with the diagnosis and management of affected patients. Glaucomas are usually categorized by the anatomy of the anterior chamber angle (open vs narrow/closed), rapidity of onset (acute vs chronic), and major etiology (primary vs secondary). Most glaucomas are primary (ie, without a contributing comorbidity); however, several coexisting ophthalmic conditions may serve as the underlying etiologies of secondary glaucomas. Chronic glaucoma occurs most commonly; thus, regular eye examinations should be performed in at-risk patients to prevent the insidious loss of vision that can develop before diagnosis. Glaucoma damages the optic nerve and retinal nerve fiber layer, leading to peripheral and central visual field defects. Elevated intraocular pressure (IOP), a crucial determinant of disease progression, remains the only modifiable risk factor; thus, all current treatments (medications, lasers, and operations) aim to reduce the IOP. Pharmacotherapy is the usual first-line therapy, but noncompliance, undesirable adverse effects, and cost limit effectiveness. Laser and surgical treatments may lower IOP significantly over long periods and may be more cost effective than pharmacotherapy, but they are plagued by greater procedural risks and frequent treatment failures. Traditional incisional procedures have recently been replaced by several novel, minimally invasive glaucoma surgeries with improved safety profiles and only minimal decreases in efficacy. Minimally invasive glaucoma surgeries have dramatically transformed the surgical management of glaucoma; nevertheless, large, randomized trials are required to assess their long-term efficacy.
format Online
Article
Text
id pubmed-9673042
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-96730422022-11-19 Updates on the Diagnosis and Management of Glaucoma Wagner, Isabella V. Stewart, Michael W. Dorairaj, Syril K. Mayo Clin Proc Innov Qual Outcomes Review Glaucoma is the leading cause of blindness throughout the world (after cataracts); therefore, general physicians should be familiar with the diagnosis and management of affected patients. Glaucomas are usually categorized by the anatomy of the anterior chamber angle (open vs narrow/closed), rapidity of onset (acute vs chronic), and major etiology (primary vs secondary). Most glaucomas are primary (ie, without a contributing comorbidity); however, several coexisting ophthalmic conditions may serve as the underlying etiologies of secondary glaucomas. Chronic glaucoma occurs most commonly; thus, regular eye examinations should be performed in at-risk patients to prevent the insidious loss of vision that can develop before diagnosis. Glaucoma damages the optic nerve and retinal nerve fiber layer, leading to peripheral and central visual field defects. Elevated intraocular pressure (IOP), a crucial determinant of disease progression, remains the only modifiable risk factor; thus, all current treatments (medications, lasers, and operations) aim to reduce the IOP. Pharmacotherapy is the usual first-line therapy, but noncompliance, undesirable adverse effects, and cost limit effectiveness. Laser and surgical treatments may lower IOP significantly over long periods and may be more cost effective than pharmacotherapy, but they are plagued by greater procedural risks and frequent treatment failures. Traditional incisional procedures have recently been replaced by several novel, minimally invasive glaucoma surgeries with improved safety profiles and only minimal decreases in efficacy. Minimally invasive glaucoma surgeries have dramatically transformed the surgical management of glaucoma; nevertheless, large, randomized trials are required to assess their long-term efficacy. Elsevier 2022-11-16 /pmc/articles/PMC9673042/ /pubmed/36405987 http://dx.doi.org/10.1016/j.mayocpiqo.2022.09.007 Text en © 2022 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Wagner, Isabella V.
Stewart, Michael W.
Dorairaj, Syril K.
Updates on the Diagnosis and Management of Glaucoma
title Updates on the Diagnosis and Management of Glaucoma
title_full Updates on the Diagnosis and Management of Glaucoma
title_fullStr Updates on the Diagnosis and Management of Glaucoma
title_full_unstemmed Updates on the Diagnosis and Management of Glaucoma
title_short Updates on the Diagnosis and Management of Glaucoma
title_sort updates on the diagnosis and management of glaucoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673042/
https://www.ncbi.nlm.nih.gov/pubmed/36405987
http://dx.doi.org/10.1016/j.mayocpiqo.2022.09.007
work_keys_str_mv AT wagnerisabellav updatesonthediagnosisandmanagementofglaucoma
AT stewartmichaelw updatesonthediagnosisandmanagementofglaucoma
AT dorairajsyrilk updatesonthediagnosisandmanagementofglaucoma